TOP > 外国特許検索 > IgA-BINDING PEPTIDE AND PURIFICATION OF IgA THEREBY

IgA-BINDING PEPTIDE AND PURIFICATION OF IgA THEREBY

外国特許コード F130007426
整理番号 S2012-0160-N0
掲載日 2013年6月24日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2012JP080875
国際公開番号 WO 2013081037
国際出願日 平成24年11月29日(2012.11.29)
国際公開日 平成25年6月6日(2013.6.6)
優先権データ
  • 特願2011-262871 (2011.11.30) JP
発明の名称 (英語) IgA-BINDING PEPTIDE AND PURIFICATION OF IgA THEREBY
発明の概要(英語) The present invention relates to a peptide which contains an amino acid sequence consisting of 14 to 18 amino acid residues and capable of binding to human IgA, and an analysis or purification method for the human IgA which uses the peptide. The peptide is represented by H-(X1)-V-C-L-S-Y-R-(X2)-(X3)-G-(X4)-P-(X5)-C-(X6)-(X7)-(X8) (I) (sequence number 1) (in the formula, each of the Xs is independently selected from the following: X1 is a Gln residue or a Met residue; X2 and X3 are independently any amino acid residue other than Cys or any one or both sides thereof are deleted; X4 is an Arg residue or the Gln residue; X5 is a Val residue or a Thr residue; X6 is a Phe residue or a Tyr residue; X7 is a Ser residue or null; X8 is a Leu residue, Thr residue, or null [in the case where X1 is the Met residue, X7 is the Ser residue or null, and X8 is null]).
従来技術、競合技術の概要(英語) BACKGROUND ART
(IgA) immunoglobulin A is, essential in the mucosal immunity as well as antibody, immunoglobulin g (IgG) present in the blood subsequent to predominant antibody class and 2, which operates on a bacteria and virus defense against infection. Is IgA, IgA dimer structure (sIgA) secreted IgA (mIgA) and monomer structure is present. Is sIgA, through Joining chain(J-chain) SS bond has a dimeric structure, is secreted into the mucus, many of the mIgA, exists in blood. In addition, is IgA, 2 of the hinge region of different lengths can be the main types of sub-type, there are IgA2 and IgA1, IgA2 Pro-rich region 13 in the absence of residues. The function of the directed to a pharmaceutical IgA, from their importance in the immune infection, in the development of mucosal vaccine have been focused (non-patent document 1 and 2), IgA is in the blood, particularly neutrophils ADCC is support by the cancer cells have been reported (non-patent document 3 and 4) from, for the treatment of cancer and autoimmune diseases that its clinical application is expanded in the same manner as in the format of a IgG antibody pharmaceuticals, also IgA antibody pharmaceuticals that target the cancer as expected (non-patent document 5).
However, the factors for inhibiting the development of a medicament to IgA as one, such as IgG affinity columns A/g protein in the manufacture of industrial, pharmaceutical scale can be supported in a purification method and has not been established. Conventional, as are several methods of IgA purification methods have been reported (non-patent document 6). For example, IgA1 recognizes specific sugar chains (non-patent document 7) and lectin Jacalin Protein A mimetic synthetic ligands (non-patent document 8) in TG19318 by the reported methods of purification IgA is, they are a problem in a binding capacity and specificity is a limitation in use. In addition, derived from a bacterium Streptococcus (non-patent document 9) surface protein from a member of the M protein family, was found IgA binding protein (non-patent document 10, patent document 1 and 11), such as IgG interaction with protein in the serum of other (non-patent document 12) or the like becomes a problem and, used as an affinity ligand specific IgA is there is a failure. On the other hand, Sandin et al., 48 residues in this Streptococcal Sir22 (M22) protein extracts QCRPSKGRKRGFCW (Streptococcal IgA-binding peptide, Sap), via Cys SS bond by dimerization, affinity than the original Sir22 protein (Kd value 3-4 nm) is somewhat inferior to the of the, a relatively high affinity (Kd value 20 nm) affinity ligands for purification of IgA (non-patent document 13) reported. The ligand is in practice, of the bound Fc IgA, sIgA, both purification mIgA, antigen-specific IgA1 and further, application to the detection of a monoclonal antibody IgA2 was also possible.
IgA binding protein in the same manner as described above, by the present inventors also IgG IgG binding peptides have been developed (patent document 2). However, IgG-binding peptide, peptides that bind to specific IgG because, as IgA-binding peptides cannot be a wobble, the difference in its specificity, of the peptide specific IgA development, the development of peptides binding IgG is completely different approach is required.
Therefore, in the art IgA purification or analysis (for the detection or quantitation) of a new technique for still has been desired earnestly.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • KAGOSHIMA UNIVERSITY
  • OTSUKA CHEMICAL CO., LTD.
  • 発明者(英語)
  • ITO Yuji
  • ITO Osamu
  • OOZONO Shinji
  • ISHITOBI Hiroyuki
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
特許の内容に興味を持たれた方、ライセンスをご希望の方は、下記「問合せ先」までお問い合わせください。

PAGE TOP

close
close
close
close
close
close